Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Provided By PR Newswire
Last update: Jan 15, 2025
– U.S. launch expected in early February –
– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –
Read more at prnewswire.com72.11
+0.73 (+1.02%)
16.38
+0.39 (+2.44%)
Find more stocks in the Stock Screener
INCY Latest News and Analysis
5 days ago - ChartmillNASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
12 days ago - ChartmillWhat's going on in today's pre-market session: S&P500 moversLet's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
13 days ago - ChartmillUncover the latest developments among S&P500 stocks in today's session.Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
13 days ago - ChartmillUncover the latest developments among S&P500 stocks in today's session.Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.
13 days ago - ChartmillGapping S&P500 stocks in Monday's sessionCurious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
18 days ago - ChartmillPromising Signs: INCYTE CORP Setting the Stage for a Breakout.Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout.
